Clinical behaviour and outcome in pediatric glioblastoma: current scenario
- PMID: 33794576
- PMCID: PMC8024182
- DOI: 10.3857/roj.2020.00591
Clinical behaviour and outcome in pediatric glioblastoma: current scenario
Abstract
Pediatric glioblastoma (pGBM) is a rare entity accounting for only approximately 3% of all childhood brain tumors. Treatment guidelines for pGBM have been extrapolated from those in adult glioblastoma. Rarity of pGBM and underrepresentation of pediatric population in major studies precludes from defining the ideal treatment protocol for these patients. Maximum safe resection is performed in most of the cases followed by postoperative radiotherapy in children over 3 years of age. Benefit of temozolomide is unclear in these patients. Here, we present the clinicopathological details and outcome of six pGBM patients treated at our institute in 2018-2019.
Keywords: Child; Genetics; Glioblastoma; Radiotherapy; Temozolomide.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
References
-
- Nikitovic M, Stanic D, Pekmezovic T, et al. Pediatric glioblastoma: a single institution experience. Childs Nerv Syst. 2016;32:97–103. - PubMed
-
- Sgouros S, Fineron PW, Hockley AD. Cerebellar astrocytoma of childhood: long-term follow-up. Childs Nerv Syst. 1995;11:89–96. - PubMed
-
- Malik N, Kumar R, Prasad KN, Kawal P, Srivastava A, Mahapatra AK. Association of matrix metalloproteinase-1 gene polymorphism with glioblastoma multiforme in a northern Indian population. J Neurooncol. 2011;102:347–52. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
